Earnings call transcript: FMC Q2 2025 beats EPS estimates, stock dips

FMC Corporation reported Q2 2025 adjusted EPS of $0.69 and revenue of $1.05 billion, both exceeding analyst expectations, with adjusted EBITDA rising 2% year-over-year. Despite the earnings beat, the stock declined 7.2% in after-hours trading, reflecting investor concerns over a 5% drop in North American sales and ongoing pricing adjustments. The company maintained its full-year 2025 guidance (excluding India), announcing a strategic exit from its India commercial business to reduce risk and free up capital, while emphasizing growth from new product launches and targeting $1.2 billion EBITDA by 2027 amidst cautious near-term analyst sentiment.

Analysis

FMC Corporation presented a mixed operational picture in its Q2 2025 results, where top- and bottom-line beats were overshadowed by forward-looking concerns, precipitating a 7.2% after-hours stock decline. The company exceeded expectations with revenue of $1.05 billion and an EPS of $0.69, driven by a 6% increase in sales volume and a 2% rise in adjusted EBITDA to $207 million. However, this performance was undermined by a significant 5% sales decline in North America and persistent pricing pressure, particularly from adjustments on diamide partner contracts. The most significant strategic development is the decision to divest its commercial business in India, a move designed to reduce working capital, de-risk the portfolio, and generate cash for debt reduction against a substantial $4.29 billion debt load. While management maintains its full-year 2025 guidance (excluding India) and a $1.2 billion EBITDA target for 2027, the near-term outlook is cautious, as evidenced by downward earnings revisions from seven analysts and a company forecast for a 1% revenue decline in Q3 (ex-India) before an anticipated 5% recovery in Q4.

Key Decisions for Investors

• Investors should assess FMC as a company in transition, balancing the near-term headwinds from North American market weakness and pricing adjustments against the potential long-term benefits of its strategic pivot away from the India commercial business.
• Monitor the execution of the India divestment closely, as the eventual sale price and terms will be critical for deleveraging the balance sheet and improving the company's financial flexibility.
• Pay close attention to Q3 and Q4 volume growth, particularly in Brazil and North America, as these results will be key indicators of whether the company's new product launches and strategic initiatives can successfully offset regional challenges and validate its growth outlook for 2026.
• Recognize that while pricing pressure from diamide partner contracts was a major factor in 2025, management commentary suggests this headwind should moderate significantly in 2026, creating a potential catalyst for margin improvement.